Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Advances Development of CAN04 Through Successful Production Scale Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Provides Update on Development Projects CAN04 and CAN10","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia IND Application for CAN04 Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Presents New Preclinical Data on CAN04 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports High Response Rates with CAN04 Combination Therapy in Nsclc and Presents Next Development Steps","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"BioInvent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent and Cantargia Sign Manufacturing Agreement for Monoclonal Antibody CAN10","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Submits Application to Start New Clinical Trial Investigating Antibody CAN04 and FOLFIRINOX in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Receives Regulatory Approval to Start Clinical Trial Investigating Nadunolimab and Folfirinox in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Broadens the Development of Nadunolimab in Three Forms of Cancer and Submits Application for Phase I\/II Trial CESTAFOUR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Expands Nadunolimab Development in Non-Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reaches Recruitment Milestone And Focuses Nadunolimab Development On Upcoming Randomized Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia's CAN10 Demonstrates Positive Activity In Systemic Sclerosis Models In New Data Presented At ACR Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Successfully Concludes Toxicity Study with CAN10 Antibody Ahead of Phase I Clinical Trial Application","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Advances TRIFOUR Trial to Randomized Stage Following Promising Early Safety and Efficacy of Nadunolimab in Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports Phase I Clinical Progress in the CAN10 Project","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIb Trial with Nadunolimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Presents New Human Data Further Supporting CAN10 in the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Cantargia AB

    Menu

    Cantargia AB

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

              Details:

              CAN10 is an investigational antibody, which binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36, which is being evaluated for the treatment of atherosclerosis.

              Lead Product(s): CAN10

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CAN10

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia

              Details:

              Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated in the IND-enabling studies for the treatment of acute myeloid leukemia.

              Lead Product(s): Nadunolimab

              Therapeutic Area: Oncology Product Name: CAN04

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Presents New Human Data Further Supporting CAN10 in the Treatment of Systemic Sclerosis

              Details:

              CAN10 is an Phase 1 investigational antibody, which binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36, which has significant value in the treatment of diseases like systemic sclerosis and myocarditis.

              Lead Product(s): CAN10

              Therapeutic Area: Immunology Product Name: CAN10

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer

              Details:

              CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.

              Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine

              Therapeutic Area: Oncology Product Name: CAN04

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIb Trial with Nadunolimab

              Details:

              CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.

              Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine

              Therapeutic Area: Oncology Product Name: CAN04

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

              Details:

              CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of triple negative breast cancer, non-small cell lung cancer & pancreatic cancer.

              Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine

              Therapeutic Area: Oncology Product Name: CAN04

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Reports Phase I Clinical Progress in the CAN10 Project

              Details:

              The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. It is under phase 1 clinical development for the treatment of Plaque Psoriasis.

              Lead Product(s): CAN10

              Therapeutic Area: Dermatology Product Name: CAN10

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Advances TRIFOUR Trial to Randomized Stage Following Promising Early Safety and Efficacy of Nadunolimab in Triple-Negative Breast Cancer

              Details:

              CAN04 (nadunolimab) antibody binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It counteracts IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy.

              Lead Product(s): Nadunolimab,Gemcitabine,Carboplatin

              Therapeutic Area: Oncology Product Name: CAN04

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia Successfully Concludes Toxicity Study with CAN10 Antibody Ahead of Phase I Clinical Trial Application

              Details:

              CAN10 antibody which, by binding IL1RAP, can block all these signalling pathways simultaneously. This function provides CAN10 with great potential for treatment of several diseases.

              Lead Product(s): CAN10

              Therapeutic Area: Immunology Product Name: CAN10

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cantargia AB

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cantargia's CAN10 Demonstrates Positive Activity In Systemic Sclerosis Models In New Data Presented At ACR Convergence 2022

              Details:

              The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.

              Lead Product(s): CAN10

              Therapeutic Area: Immunology Product Name: CAN10

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY